SCHEMBL22170872

SCHEMBL22170872

Cc1cccc2sc(C=O)nc12

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 3/20 0.56
▸ PKM P14618 1/20 0.49
▸ MAPT P10636 8/20 0.48
▸ GAA P10253 1/20 0.44
▸ MEN1 O00255 7/20 0.42
▸ KMT2A Q03164 7/20 0.42
▸ KDM4E B2RXH2 3/20 0.42
▸ LMNA P02545 3/20 0.42
▸ ALOX15 P16050 2/20 0.42
▸ HPGD P15428 2/20 0.42
▸ POLB P06746 2/20 0.42
▸ L3MBTL1 Q9Y468 2/20 0.42
▸ USP2 O75604 1/20 0.42
▸ MCL1 Q07820 1/20 0.42
▸ ESR2 Q92731 1/20 0.42
▸ HSD17B10 Q99714 1/20 0.42
▸ TDP1 Q9NUW8 1/20 0.42
▸ MAPK1 P28482 1/20 0.42
▸ ACP1 P24666 1/20 0.41
▸ SMN1; SMN2 Q16637 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14127134 0.84 ALDH1A1 (0.58) ALDH1A1PKMMAPTGAAMEN1
SCHEMBL25366862 0.79 SMN1; SMN2 (0.56) ALDH1A1PKMMAPTGAAMEN1
SCHEMBL8898795 0.79 PSMD14 (0.36) ALDH1A1PKMMAPTGAAMEN1
SCHEMBL31595929 0.79 SMN1; SMN2 (0.56) ALDH1A1PKMMAPTGAAMEN1
SCHEMBL1770469 0.79 NPC1 (0.46) ALDH1A1MAPTGAAMEN1KMT2A
SCHEMBL3254919 0.78 ALDH1A1 (0.59) ALDH1A1MAPTGAAMEN1KMT2A
SCHEMBL25369141 0.78 PARP1 (0.39) ALDH1A1GAAMEN1KMT2AKDM4E
Formamide SCHEMBL28482328 0.77 ALDH1A1 (0.59) ALDH1A1PKMMAPTGAAMEN1
SCHEMBL1748098 0.75 ALDH1A1 (0.66) ALDH1A1PKMMAPTGAAMEN1
SCHEMBL24928789 0.75 MAPT (0.58) ALDH1A1PKMMAPTGAAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230265104-A1 NOVEL HETEROCYCLIC COMPOUNDS Prism BioLab Co., Ltd. (JP) 2023-08-24 — — US disclosed
CN-108101863-B Method for synthesizing benzothiazole-2-ketone derivative by using carbonyl sulfide and disulfide as raw materials 内蒙古工业大学 2022-01-25 — — CN disclosed
EP-3204352-B1 INHIBITORS OF LYSINE GINGIPAIN CORTEXYME INC (US) 2020-07-01 — — EP disclosed
CN-108101863-A It is a kind of using carbonyl sulfur and disulphide as the method for Material synthesis benzothiazole -2- ketones derivants 内蒙古工业大学 2018-06-01 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230265104-A1 NOVEL HETEROCYCLIC COMPOUNDS MKI67, CCNI, KRAS ALDH1A1 345/4885PKM 1992/4885MAPT 4332/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback